WealthPLAN Partners LLC Buys New Position in Edwards Lifesciences Corporation $EW

WealthPLAN Partners LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 7,010 shares of the medical research company’s stock, valued at approximately $545,000.

Other institutional investors also recently modified their holdings of the company. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences during the second quarter worth $28,000. True Wealth Design LLC grew its holdings in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the period. NewSquare Capital LLC lifted its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. Rakuten Securities Inc. boosted its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $30,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 57,824 shares of company stock worth $4,863,323 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $82.99 on Thursday. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm has a 50-day moving average of $85.06 and a 200-day moving average of $80.47. The company has a market cap of $48.16 billion, a P/E ratio of 35.77, a P/E/G ratio of 3.36 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on EW shares. The Goldman Sachs Group restated a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a report on Friday, January 9th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Evercore ISI reaffirmed an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Barclays restated an “overweight” rating and set a $104.00 price objective (up previously from $103.00) on shares of Edwards Lifesciences in a report on Monday. Finally, Wells Fargo & Company set a $100.00 target price on Edwards Lifesciences in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.87.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.